Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi): worried about 2019, investors better be!

January 21, 2019

   RMi is the source investors and traders need – it’s more than opinion; the facts and truth need to be recognized! I post about “indication intelligence” devoting my time to collection and analysis of information for insight into sector vulnerabilities and strengths.   My writing is “that warning analysis is NOT a commodity. However, there are times, when the likelihood of conclusions are inescapable!        

Stemline Therapeutics (STML) priced an 8.88 M share offering at $9.00 per share

January 16, 2019

STML closed up at $0.86 (+9.47%) to $9.94 Expected gross proceeds to Stemline are $80 million. Due to demand, this offering was upsized from the previously announced 6,600,000 shares. STML has also granted the underwriters a 30-day option to purchase up to 1,333,333 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. BUY

Alnylam Pharmaceuticals (ALNY) priced 5 M share offering at $77.50

January 15, 2019

ALNY closed down -$3.57 or -4.25% to $80.45 after closing down -$5.10 on Monday The gross proceeds to ALNY from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $387.5 M.  BUY

Roll Call

The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.